Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)

Leukemia volume 23, pages 2153–2155 (2009)Cite this article

The interstitial deletion del(14)(q24.1q32.33) is a recurrent chromosomal change in B-cell chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.1, 2 The break points of this deletion are located in the immunoglobulin heavy chain (IGH)-locus in 14q32.33 and in a region in 14q24.1 containing the ZFP36L1 gene (1and our own unpublished observations). Activation of a candidate oncogene centromeric of the deletion break point in 14q24.1 through juxtaposition to the IGH locus, yet could not be unambiguously shown.1 An alternative hypothesis is that the deletion might inactivate a tumor suppressor gene.

Among many other genes, the TNF receptor-associated factor 3 (TRAF3)-gene in 14q32.32 is located within the deleted region. The TRAF3 protein negatively regulates the NF-κB pathway and has been shown to be recurrently affected by biallelic TRAF3 deletion and inactivating mutation in multiple myeloma and Waldenström's macroglobulinemia.3, 4, 5 Furthermore, B-cell-specific TRAF3−/− mice show remarkably prolonged B-cell survival and highly expanded B-cell compartments in secondary lymphoid organs.6 These facts qualify TRAF3 as a candidate tumor suppressor gene involved in lymphomagenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P et al. Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. Leukemia 2007; 21: 2079–2083.

    Article  CAS  Google Scholar 

  2. Tilly H, Bastard C, Halkin E, Lenormand B, Bizet M, Dauce JP et al. Del(14)(q22) in diffuse B-cell lymphocytic lymphoma. Am J Clin Pathol 1988; 89: 109–113.

    Article  CAS  Google Scholar 

  3. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115–130.

    Article  CAS  Google Scholar 

  4. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131–144.

    Article  CAS  Google Scholar 

  5. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom′s macroglobulinemia. Cancer Res 2009; 69: 3579–3588.

    Article  CAS  Google Scholar 

  6. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA . Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007; 27: 253–267.

    Article  Google Scholar 

  7. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G . Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem 2007; 282: 3688–3694.

    Article  CAS  Google Scholar 

  8. Basseres DS, Baldwin AS . Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817–6830.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully thank Kerstin Runde, Reina Zühlke-Jenisch, Magret Ratjen, Dorit Schuster, Claudia Becher and Ursula Schnaidt for their technical assistance. Supported by the Network Project of the Deutsche Krebshilfe ‘Molecular Mechanisms in Malignant Lymphomas’ 70-3173-TR3, the Wilhelm Sander-Stiftung 2005.168.2 and RETICS. Instituto de Salud Carlos III, RETICS. Convocatoria 2008. RD07/0020/2004.

Author information

Authors and Affiliations

  1. Institute of Human Genetics, Christian-Albrechts University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany

    I Nagel, S Bug, H Tönnies, O Ammerpohl, J Richter, I Vater, J I Martin-Subero, S Gesk, L Harder & R Siebert

  2. Laboratoire d’Hematologie et de cytogénétique, Centre Hospitalier Lyon Sud, Lyon, France

    E Callet-Bauchu

  3. Department of Genetics, University of Navarra, Pamplona, Spain

    M J Calasanz

  4. Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain

    J A Martinez-Climent

  5. Groupe d’Etude des Proliférations Lymphoides (GPL), European Institute for Peptides Research (IFRMP23), Centre Henri Becquerel, Rouen, France

    C Bastard

  6. Servei de Patologia, Laboratori de Citogenètica Molecular, Hospital del Mar, GRETNHE, IMIM, Barcelona, Spain

    M Salido

  7. MVZ Dr Eberhard and Partner, Dortmund, Germany

    E Schroers

  8. Medical Research Council (MRC) Toxicology Unit, University of Leicester, Leicester, UK

    A Majid & M J S Dyer

Authors
  1. I Nagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bug
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Tönnies
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Ammerpohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Vater
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Callet-Bauchu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M J Calasanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J A Martinez-Climent
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Bastard
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Salido
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Schroers
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J I Martin-Subero
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S Gesk
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. L Harder
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Majid
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M J S Dyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. R Siebert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Nagel.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagel, I., Bug, S., Tönnies, H. et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 23, 2153–2155 (2009). https://doi.org/10.1038/leu.2009.149

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.149

Search

Advanced search

Quick links